​​​
  1. Cipla gets USFDA nod for lipid regulating tablets

Cipla gets USFDA nod for lipid regulating tablets

The company "has received final approval for its abbreviated new drug application (ANDA) for Fenofibrate tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA)," Cipla said in a BSE filing

By: | New Delhi | Updated: December 19, 2016 3:07 PM
Drug firm Cipla has received final approval from the US health regulator for lipid regulating Fenofibrate tablets. (AFP) Drug firm Cipla has received final approval from the US health regulator for lipid regulating Fenofibrate tablets. (AFP)

Drug firm Cipla has received final approval from the US health regulator for lipid regulating Fenofibrate tablets. The company “has received final approval for its abbreviated new drug application (ANDA) for Fenofibrate tablets USP 48mg and 145mg, from the United States Food and Drug Administration (USFDA),” Cipla said in a BSE filing.

The tablets are generic versions of AbbVie’s Tricor tablets, it added.

You may also like to watch this video:

“Tricor tablets and generic equivalents had US sales of approximately USD 307 million for the 12-month period ending October 2016, according to IMS Health,” Cipla said. The company’s portfolio includes over 1,000 products across a wide range of therapeutic categories. Shares of Cipla were trading 0.76 per cent up at Rs 570.30 on BSE.

Get live Stock Prices from BSE and NSE and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Go to Top